Influenza A virus infection kinetics: quantitative data and models

Advanced Review

Amber M. Smith, Alan S. Perelson

Published Online: Dec 31 2010

DOI: 10.1002/wsbm.129

How to cite this article
Download citation
Contact the editor about this article
Authors: submit updates and notes
Comment on this article
Share

Full article on Wiley Online Library: HTML PDF

Can't access this content? Tell your librarian.

Influenza A virus is an important respiratory pathogen that poses a considerable threat to public health each year during seasonal epidemics and even more so when a pandemic strain emerges. Understanding the mechanisms involved in controlling an influenza infection within a host is important and could result in new and effective treatment strategies. Kinetic models of influenza viral growth and decay can summarize data and evaluate the biological parameters governing interactions between the virus and the host. Here we discuss recent viral kinetic models for influenza. We show how these models have been used to provide insight into influenza pathogenesis and treatment, and we highlight the challenges of viral kinetic analysis, including accurate model formulation, estimation of important parameters, and the collection of detailed data sets that measure multiple variables simultaneously. WIREs Syst Biol Med 2011 3 429–445 DOI: 10.1002/wsbm.129

This WIREs title offers downloadable PowerPoint presentations of figures for non-profit, educational use, provided the content is not modified and full credit is given to the author and publication.

Download a PowerPoint presentation of all images

Figure 1.

Schematic diagram of the viral dynamics models. (a) Classic model of viral dynamics. Target cells (T) are supplied at constant rate s and die at rate d per day. These cells become infected at rate βV per day. Free virions are produced from infected cells (I) at a rate p and are removed at a rate c. Infected cells are lost at a rate δ. (b) Acute virus infection model modified from the classic model. Target cell regeneration and death are not included. Infected cells were split into two classes, I₁ and I₂, where virus production initially undergoes an eclipse phase (k).

[ Normal View 44K | Magnified View 76K ]

References

1 Taubenberger, JK, Morens, DM. The pathology of influenza virus infections. Ann Rev Pathol 2008, 3: 499–522.
2 Wright, PF, Neumann, G, Kawaoka, Y. %22Orthomyxoviruses%22. In: Knipe D, Howley P, Griffin D, Lamb R, Martin M, Roizman B, Straus S, eds. Fields Virology. 5th ed. Philadelphia, PA: Lippincott/The Williams %26 Wilkins Co.; 2007, 1691–1740.
3 Perelson, AS. Modelling viral and immune system dynamics. Nat Rev Immunol 2002, 2:28–36.
4 Schulze‐Horsel, J, Schulze, M, Agalaridis, G, Genzel, Y, Reichl, U. Infection dynamics and virus‐induced apoptosis in cell culture‐based influenza vaccine production‐‐Flow cytometry and mathematical modeling. Vaccine 2009, 27:2712–2722.
5 Smith, AM, Adler, FR, McAuley, JL, Gutenkunst, RN, Ribeiro, RM, McCullers, JA, Perelson, AS. Effect of 1918 PB1‐F2 expression on influenza A virus infection kinetics. PLoS Comput Biol. Submitted for publication.
6 Hancioglu, B, Swigon, D, Clermont, G. A dynamical model of human immune response to influenza A virus infection. J Theor Biol 2007, 246:70–86.
7 Handel, A, Longini, IM, Antia, R. Towards a quantitative understanding of the within‐host dynamics of influenza A infections. J R Soc Interface 2010, 7: 35–47.
8 Lee, HY, Topham, DJ, Park, SY, Hollenbaugh, J, Treanor, J, Mosmann, TR, Jin, X, Ward, B, Miao, H, Holden‐Wiltse, J, et al. Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol 2009, 83:7151–7165.
9 Miao, H, Hollenbaugh, JA, Zand, MS, Holden‐Wiltse, J, Mosmann, TR, Perelson, AS, Wu, H, Topham, DJ. Quantifying the early immune response and adaptive immune response kinetics in mice infected by influenza A virus. J Virol 2010, 84:6687–6698.
10 Saenz, RA, Quinlivan, M, Elton, D, MacRae, S, Blunden, AS, Mumford, JA, Daly, JM, Digard, P, Cullinane, A, Grenfell, BT, et al. Dynamics of influenza virus infection and pathology. J Virol 2010, 84:3974–3983.
11 Baccam, P, Beauchemin, C, Macken, CA, Hayden, FG, Perelson, AS. Kinetics of influenza A virus infection in humans. J Virol 2006, 80:7590–7599.
12 Beauchemin, CAA, McSharry, JJ, Drusano, GL, Nguyen, JT, Went, GT, Ribeiro, RM, Perelson, AS. Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol 2008, 254:439–451.
13 Handel, A, Longini, IM Jr, Antia, R. Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput Biol 2007, 3:e240.
14 Holder, BP, Simon, P, Liao, LE, Abed, Y, Bouhy, X, Beauchemin, CAA, Boivin, G. Assessing fitness of an oseltamivir‐resistant seasonal A/H1N1 influenza strain using a mathematical model. PLoS ONE. Submitted for publication.
15 Möhler, L, Flockerzi, D, Sann, H, Reichl, U. Mathematical model of influenza A virus production in large‐scale microcarrier culture. Biotechnol Bioeng 2005, 90:46–58.
16 Genzel, Y, Behrendt, I, König, S, Sann, H, Reichl, U. Metabolism of MDCK cells during cell growth and influenza virus production in large‐scale microcarrier culture. Vaccine 2004, 22:2202–2208.
17 Bocharov, GA, Romanyukha, AA. Mathematical model of antiviral immune response III. Influenza A virus infection. J Theor Biol 1994, 167:323–360.
18 Holder, B, Beauchemin, C. In‐host influenza modeling and non‐exponential delays. BMC Public Health. Submitted for publication.
19 Tridane, A, Kuang, Y. Modeling the interaction of cytotoxic T lymphocytes and influenza virus infected epithelial cells. Math Biosci Eng 2010, 7:171–185.
20 Smith, DJ, Forrest, S, Ackley, DH, Perelson, AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci USA 1999, 96:14001–14006.
21 Beauchemin, C, Samuel, J, Tuszynski, J. A simple cellular automaton model for influenza A viral infections. J Theor Biol 2005, 232:223–234.
22 Smith, AM, Adler, FR, Perelson, AS. An accurate two‐phase approximate solution to an acute viral infection model. J Math Biol 2010, 60:711–726.
23 Sidorenko, Y, Reichl, U. Structured model of influenza virus replication in MDCK cells. Biotechnol Bioeng 2004, 88:1–14.
24 Nowak, MA, May, R. Virus Dynamics: Mathematical Principles of Immunology and Virology. New York: Oxford University Press; 2001.
25 Smith, AM, Ribeiro, RM. Modeling the viral dynamics of influenza A virus infection. Crit Rev Immunol 2010, 30:291–298.
26 Herz, AV, Bonhoeffer, S, Anderson, RM, May, RM, Nowak, MA. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Proc Natl Acad Sci USA 1996, 93:7247–7251.
27 Mittler, JE, Sulzer, B, Neumann, AU, Perelson, AS. Influence of delayed viral production on viral dynamics in HIV‐1 infected patients. Math Biosci 1998, 152: 143–163.
28 Stafford, MA, Corey, L, Cao, Y, Daar, ES, Ho, DD, Perelson, AS. Modeling plasma virus concentration during primary HIV infection. J Theor Biol 2000, 203:285–301.
29 Murphy, BR, Rennels, MB, Douglas, R Jr, Betts, RF, Couch, RB, Cate, T Jr, Chanock, RM, Kendal, AP, Maassab, HF, Suwanagool, S, et al. Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts‐1A2 and cold‐adapted recombinant viruses in seronegative adult volunteers. Infect Immun 1980, 29:348–355.
30 Hayden, FG, Treanor, JJ, Betts, RF, Lobo, M, Esinhart, JD, Hussey, EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. J Am Med Assoc 1996, 275:295–299.
31 Quinlivan, M, Nelly, M, Prendergast, M, Breathnach, C, Horohov, D, Arkins, S, Chiang, YW, Chu, HJ, Ng, T, Cullinane, A. Pro‐inflammatory and antiviral cytokine expression in vaccinated and unvaccinated horses exposed to equine influenza virus. Vaccine 2007, 25:7056–7064.
32 Iwasaki, T, Nozima, T. Defense mechanisms against primary influenza virus infection in mice: I. The roles of interferon and neutralizing antibodies and thymus dependence of interferon and antibody production. J Immunol 1977, 118:256–263.
33 Conenello, GM, Zamarin, D, Perrone, LA, Tumpey, T, Palese, P. A single mutation in the PB1‐F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog 2007, 3:e141.
34 McAuley, JL, Chipuk, JE, Boyd, KL, Van, De Velde, N, Green, DR, McCullers, JA. PB1‐F2 proteins from H5N1 and 20th century pandemic influenza viruses cause immunopathology. PLoS Pathog 2010, 6:680–689.
35 McAuley, JL, Hornung, F, Boyd, KL, Smith, AM, McKeon, R, Bennink, J, Yewdell, JW, McCullers, JA. Expression of the 1918 influenza A virus PB1‐F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host %26 Microbe 2007, 2:240–249.
36 Zamarin, D, Ortigoza, MB, Palese, P. Influenza A virus PB1‐F2 protein contributes to viral pathogenesis in mice. J Virol 2006, 80:7976–7983.
37 Doherty, PC, Topham, DJ, Tripp, RA, Cardin, RD, Brooks, JW, Stevenson, PG. Effector CD4+ and CD8+ T‐cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997, 159:105–117.
38 Centre for Disease Control and Prevention. Clinical signs and symptoms of influenza. 2010. Available at: http://www.cdc.gov/flu/professionals/acip/clinical.htm (Accessed July 19, 2010).
39 Belz, GT, Wodarz, D, Diaz, G, Nowak, MA, Doherty, PC. Compromised influenza virus‐specific CD8+−T‐cell memory in CD4+−T‐cell‐deficient mice. J Virol 2002, 76:12388–12393.
40 Julkunen, I, Melén, K, Nyqvist, M, Pirhonen, J, Sareneva, T, Matikainen, S. Inflammatory responses in influenza A virus infection. Vaccine 2000, 19:S32–S37.
41 García‐Sastre, A, Durbin, RK, Zheng, H, Palese, P, Gertner, R, Levy, DE, Durbin, JE. The role of interferon in influenza virus tissue tropism. J Virol 1998, 72: 8550–8558.
42 Santoli, D, Trinchieri, G, Koprowski, H. Cell‐mediated cytotoxicity against virus‐infected target cells in humans: II. Interferon induction and activation of natural killer cells. J Immunol 1978, 121:532–538.
43 Price, GE, Gaszewska‐Mastarlarz, A, Moskophidis, D. The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice. J Virol 2000, 74:3996–4003.
44 Chang, DB, Young, CS. Simple scaling laws for influenza A rise time, duration, and severity. J Theor Biol 2007, 246:621–635.
45 Neumann, AU, Lam, NP, Dahari, H, Gretch, DR, Wiley, TE, Layden, TJ, Perelson, AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon‐therapy. Science 1998, 282:103–107.
46 Colonna, M, Krug, A, Cella, M. Interferon‐producing cells: on the front line in immune responses against pathogens. Curr Opin Immunol 2002, 14:373–379.
47 Topham, DJ, Doherty, PC. Clearance of an influenza A virus by CD4+ T cells is inefficient in the absence of B cells. J Virol 1998, 72:882–885.
48 Clements, ML, Betts, RF, Tierney, EL, Murphy, BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild‐type virus. J Clin Microbiol 1986, 24:157–160.
49 Johansson, BE, Bucher, DJ, Kilbourne, ED. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 1989, 63:1239–1246.
50 Centre for Disease Control and Prevention. Interim antiviral guidance for 2008‐09. 2008. http://www.cdc.gov/flu/professionals/antivirals/ (Accessed July 19, 2010).
51 De Clercq, E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 2006, 5:1015–1025.
52 Gubareva, LV, Kaiser, L, Hayden, FG. Influenza virus neuraminidase inhibitors. Lancet 2000, 355:827–835.
53 Jefferson, T, Demicheli, V, Rivetti, D, Jones, M, Di, Pietrantonj C, Rivetti, A. Antivirals for influenza in healthy adults: systematic review. Lancet 2006, 367:303–313.
54 Hayden, FG, Aoki, FY. %22Amantadine, rimantadine, and related agents, antiviral agents%22. In: Yu V, Meigan T, Barriere S, eds. Antimicrobial Therapy and Vaccines. Baltimore, MD: Williams and Wilkins; 1999.
55 Aoki, FY, Macleod, MD, Paggiaro, P, Carewicz, O, El Sawy, A, Wat, C, Griffiths, M, Waalberg, E, Ward, P. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003, 51:123–129.
56 Carrat, F, Vergu, E, Ferguson, NM, Lemaitre, M, Cauchemez, S, Leach, S, Valleron, AJ. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008, 167:775–785.
57 Chen, GL, Lamirande, EW, Yang, CF, Jin, H, Kemble, G, Subbarao, K. Evaluation of replication and cross‐reactive antibody response of H2 influenza subtype viruses in mice and ferrets. J Virol. In press.
58 Durr, FE, Lindh, HF. Efficacy of ribavirin against influenza virus in tissue culture and in mice. Ann NY Acad Sci 2006, 255:366–371.
59 Fujisawa, H. Neutrophils play an essential role in cooperation with antibody in both protection against and recovery from pulmonary infection with influenza virus in mice. J Virol 2008, 82:2772–2783.
60 Herfst, S, Chutinimitkul, S, Ye, J, de, Wit E, Munster, VJ, Schrauwen, EJA, Bestebroer, TM, Jonges, M, Meijer, A, Koopmans, M, et al. Introduction of virulence markers in PB2 of pandemic swine‐origin influenza virus does not result in enhanced virulence or transmission. J Virol 2010, 84:3752–3758.
61 Larson, EW, Dominik, JW, Rowberg, AH, Higbee, GA. Influenza virus population dynamics in the respiratory tract of experimentally infected mice. Infect Immun 1976, 13:438–447.
62 McAuley, JL, Zhang, K, McCullers, JA. The effects of influenza A virus PB1‐F2 protein on polymerase activity are strain specific and do not impact pathogenesis. J Virol 2010, 84:558–564.
63 Seo, SH, Hoffmann, E, Webster, RG. Lethal H5N1 influenza viruses escape host anti‐viral cytokine responses. Nat Med 2002, 8:950–954.
64 Szretter, KJ, Gangappa, S, Belser, JA, Zeng, H, Chen, H, Matsuoka, Y, Sambhara, S, Swayne, DE, Tumpey, TM, Katz, JM. Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol 2009, 83:5825–5834.
65 Tang, X, Chong, KT. Histopathology and growth kinetics of influenza viruses (H1N1 and H3N2) in the upper and lower airways of guinea pigs. J Gen Virol 2009, 90:386–391.
66 Toapanta, FR, Ross, TM. . Impaired immune responses in the lungs of aged mice following influenza infection. Resp Res 2009, 10:112.
67 Van, Reeth K, Gregory, V, Hay, A, Pensaert, M. Protection against a European H1N2 swine influenza virus in pigs previously infected with H1N1 and/or H3N2 subtypes. Vaccine 2003, 21:1375–1381.
68 Zitzow, LA, Rowe, T, Morken, T, Shieh, WJ, Zaki, S, Katz, JM. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 2002, 76:4420–4429.
69 Eccles, R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis 2005, 5:718–725.
70 Hayden, FG, Fritz, RS, Lobo, MC, Alvord, WG, Strober, W, Straus, SE. Local and systemic cytokine responses during experimental human influenza A virus infection. J Clin Invest 1998, 101:643–649.
71 La, Gruta NL, Kedzierska, K, Stambas, J, Doherty, PC. A question of self‐preservation: immunopathology in influenza virus infection. Immunol Cell Biol 2007, 85:85–92.
72 Barbé, F, Atanasova, K, Van Reeth, K. Cytokines and acute phase proteins associated with acute swine influenza infection in pigs. Vet J. In press.
73 Conn, CA, McClellan, JL, Maassab, HF, Smitka, CW, Majde, JA, Kluger, MJ. Cytokines and the acute phase response to influenza virus in mice. Am J Physiol Reg I 1995, 268: R78–R84.
74 Desmet, EA, Hollenbaugh, JA, Sime, PJ, Wright, TW, Topham, DJ, Sant, AJ, Takimoto, T, Dewhurst, S. Mixed lineage kinase 3 deficiency delays viral clearance in the lung and is associated with diminished influenza‐induced cytopathic effect in infected cells. Virology 2010, 400:224–232.
75 Fritz, RS, Hayden, FG, Calfee, DP, Cass, LMR, Peng, AW, Alvord, WG, Strober, W, Straus, SE. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo‐controlled trial of intravenous zanamivir treatment. J Infect Dis 1999, 180:586–593.
76 Grebe, KM, Takeda, K, Hickman, HD, Bailey, AM, Embry, AC, Bennink, JR, Yewdell, JW. Cutting edge: Sympathetic nervous system increases proinflammatory cytokines and exacerbates influenza A virus pathogenesis. J Immunol 2010, 184:540–544.
77 Hennet, T, Ziltener, HJ, Frei, K, Peterhans, E. A kinetic study of immune mediators in the lungs of mice infected with influenza A virus. J Immunol 1992, 149:932–939.
78 Kim, HM, Lee, YW, Lee, KJ, Kim, HS, Cho, SW, Van Rooijen, N, Guan, Y, Seo, SH. Alveolar macrophages are indispensable for controlling influenza viruses in lungs of pigs. J Virol 2008, 82:4265–4274.
79 Kaufmann, A, Salentin, R, Meyer, RG, Bussfeld, D, Pauligk, C, Fesq, H, Hofmann, P, Nain, M, Gemsa, D, Sprenger, H. Defense against influenza A virus infection: essential role of the chemokine system. Immunobiology 2001, 204:603–613.
80 Skoner, DP, Gentile, DA, Patel, A, Doyle, WJ. Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus. J Infect Dis 1999, 180:10–14.
81 Tumpey, TM, Lu, X, Morken, T, Zaki, SR, Katz, JM. Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J Virol 2000, 74:6105–6116.
82 Wareing, MD, Lyon, AB, Lu, B, Gerard, C, Sarawar, SR. Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice. J Leukoc Biol 2004, 76:886–895.
83 Wu, W, Booth, JL, Duggan, ES, Wu, S, Patel, KB, Coggeshall, KM, Metcalf, JP. Innate immune response to H3N2 and H1N1 influenza virus infection in a human lung organ culture model. Virology 2010, 396: 178–188.
84 Perrone, LA, Plowden, JK, García‐Sastre, A, Katz, JM, Tumpey, TM. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog 2008, 4:e1000115.
85 Tate, M, Brooks, A, Reading, P. The role of neutrophils in the upper and lower respiratory tract during influenza virus infection of mice. Respir Res 2008, 9:57.
86 Tate, MD, Deng, YM, Jones, JE, Anderson, GP, Brooks, AG, Reading, PC. Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J Immunol 2009, 183:7441–7450.
87 Tumpey, TM, García‐Sastre, A, Taubenberger, JK, Palese, P, Swayne, DE, Pantin‐Jackwood, MJ, Schultz‐Cherry, S, Solórzano, A, Van, Rooijen N, Katz, JM, et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol 2005, 79: 14933–14944.
88 Fujisawa, H. Inhibitory role of neutrophils on influenza virus multiplication in the lungs of mice. Microbiol Immunol 2001, 45:679–688.
89 Bender, B, Small, P Jr. Influenza: pathogenesis and host defense. Sem Resp Infect 1992, 7:38–45.
90 Nain, M, Hinder, F, Gong, JH, Schmidt, A, Bender, A, Sprenger, H, Gemsa, D. Tumor necrosis factor‐alpha production of influenza A virus‐infected macrophages and potentiating effect of lipopolysaccharides. J Immunol 1990, 145:1921–1928.
91 Reading, PC, Whitney, PG, Pickett, DL, Tate, MD, Brooks, AG. Influenza viruses differ in ability to infect macrophages and to induce a local inflammatory response following intraperitoneal injection of mice. Immunol Cell Biol 2010, 88:1–10.
92 Sareneva, T, Matikainen, S, Kurimoto, M, Julkunen, I. Influenza A virus‐induced IFN‐α/β and IL‐18 synergistically enhance IFN‐γ gene expression in human T cells. J Immunol 1998, 160:6032–6038.
93 Matikainen, S, Pirhonen, J, Miettinen, M, Lehtonen, A, Govenius‐Vintola, C, Sareneva, T, Julkunen, I. Influenza A and sendai viruses induce differential chemokine gene expression and transcription factor activation in human macrophages. Virology 2000, 276:138–147.
94 Van, Riel D, Munster, VJ, De, Wit E, Rimmelzwaan, GF, Fouchier, RAM, Osterhaus, ADME, Kuiken, T. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am J Pathol 2007, 171:1215–1223.
95 Bender, B, Small, P Jr. Heterotypic immune mice lose protection against influenza virus infection with senescence. J Infect Dis 1993, 168:873–880.
96 Bjornson, A, Mellencamp, M, Schiff, G. Complement is activated in the upper respiratory tract during influenza virus infection. Am Rev Respir Dis 1991, 143:1062–1066.
97 Douglas, R Jr, Betts, R, Simons, R, Hogan, P, Roth, F. Evaluation of a topical interferon inducer in experimental influenza infection in volunteers. Antimicrob Agents Ch 1975, 8:684–687.
98 Hale, BG, Steel, J, Medina, RA, Manicassamy, B, Ye, J, Hickman, D, Hai, R, Schmolke, M, Lowen, AC, Perez, DR, et al. Inefficient control of host gene expression by the 2009 pandemic H1N1 influenza A virus NS1 protein. J Virol 2010, 84:6909–6922.
99 Jao, R, Wheelock, E, Jackson, G. Production of interferon in volunteers infected with Asian influenza. J Infect Dis 1970, 121:419–426.
100 Murphy, BR, Chanock, RM, Douglas, RG, Betts, RF, Waterman, DH, Holley, HP, Hoover, DL, Suwanagool, S, Nalin, DR, Levine, MM. Temperature‐sensitive mutants of influenza A virus: evaluation of the Alaska/77‐ts‐1 A 2 temperature‐sensitive recombinant virus in seronegative adult volunteers. Arch Virol 1980, 65:169–173.
101 Reuman, PD, Bernstein, DI, Keefer, MC, Young, EC, Sherwood, JR, Schiff, GM. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antivir Res 1989, 11:27–40.
102 Perelson, AS, Essunger, P, Cao, Y, Vesaneir, M, Hurley, A, Sakselat, K, Markowitz, M, Ho, DD. Decay characteristics of HIV‐1‐infected compartments during combination therapy. Nature 1997, 387:188–191.
103 Barroso, L, Treanor, J, Gubareva, L, Hayden, FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005, 10:901–910.
104 Germann, TC, Kadau, K, Longini, IM Jr, Macken, CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 2006, 103: 5935–5940.
105 Mills, CE, Robins, JM, Lipsitch, M. Transmissibility of 1918 pandemic influenza. Nature 2004, 432:904–906.
106 Gonzalez, SF, Lukacs‐Kornek, V, Kuligowski, MP, Pitcher, LA, Degn, SE, Kim, YA, Cloninger, MJ, Martinez‐Pomares, L, Gordon, S, Turley, SJ, et al. Capture of influenza by medullary dendritic cells via SIGN‐R1 is essential for humoral immunity in draining lymph nodes. Nat Immunol 2010, 11:427–434.
107 Kash, JC, Tumpey, TM, Proll, SC, Carter, V, Perwitasari, O, Thomas, MJ, Basler, CF, Palese, P, Taubenberger, JK, García‐Sastre, A, et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006, 443:578–581.
108 Kobasa, D, Jones, SM, Shinya, K, Kash, JC, Copps, J, Ebihara, H, Hatta, Y, Kim, JH, Halfmann, P, Hatta, M, et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007, 445:319–323.
109 Rowe, T, León, AJ, Crevar, CJ, Carter, DM, Xu, L, Ran, L, Fang, Y, Cameron, CM, Cameron, MJ, Banner, D, et al. Modeling host responses in ferrets during A/California/07/2009 influenza infection. Virology 2010, 401:257–265.
110 Holford, NH, Sheiner, LB. Pharmacokinetic and pharmacodynamic modeling in vivo. Crit Rev Bioeng 1981, 5:273–322.

blog comments powered by Disqus

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

In the Spotlight

Philip Benfey

Is intrigued by one of the key questions in developmental biology: how cells acquire their identities. This is an important question in human development, where stem cells divide and differentiate into skin, muscle, fat etc. It is equally central to plant development, where most organs and cells are formed from stem cell populations known as meristems. The Benfey lab addresses this question using a combination of genetics, molecular biology, and genomics to identify and characterize the genes that regulate formation of the root in the plant model system, Arabidopsis thaliana. The choice of the root as a model was based on the simplicity of its organization and its stereotyped developmental program.

Learn More

Article Title	Influenza A virus infection kinetics: quantitative data and models
* Name
* E-mail
* Note

Influenza A virus infection kinetics: quantitative data and models

Related Articles

Browse by Topic

Access to this WIREs title is by subscription only.

The latest WIREs articles in your inbox

In the Spotlight

Twitter: WIREsSysBioMed Follow us on Twitter